A recent observational study published in the Canadian Medical Association Journal has uncovered a striking increase in prescriptions for stimulant medications among adults in Ontario, Canada, particularly following the onset of the COVID-19 pandemic. These stimulants, primarily prescribed to manage attention deficit hyperactivity disorder (ADHD), have historically been concentrated in pediatric populations. However, data spanning from January 2016 through June 2024 reveals not only the expansion of stimulant usage into adult demographics but also significant shifts in prescribing behaviors and diagnostic awareness.
Traditionally, ADHD and corresponding stimulant treatment were predominantly associated with children and adolescents. Yet over the last two decades, adult diagnosis and treatment of ADHD have experienced a remarkable rise worldwide, a phenomenon that appears to have accelerated sharply with the unique social, psychological, and medical pressures induced by the pandemic. This study sought to dissect the underlying trends within Canada, focusing on demographic distributions, prescribing sources, and potential drivers of increased stimulant initiation.
The research documented that 327,053 adults in Ontario received at least one new stimulant prescription during the examined period. This cohort was slightly majority female at 55%, with a median age of 31 years, and predominantly urban-based (91%). After an initial slump coinciding with the early pandemic phase, new stimulant prescriptions surged precipitously, with the most pronounced elevation observed in the 18- to 24-year-old bracket—a group that also manifested the highest per capita rates. An unexpected gender trend emerged as well: whereas pre-pandemic stimulant prescriptions were evenly distributed between males and females, the pandemic period saw females consistently outpacing males in all age categories.
This gender disparity aligns with evolving understandings of ADHD as an often underrecognized condition in adult women. Historically, clinical attention and diagnostic criteria skewed towards male presentations of ADHD, overlooking subtler symptomatology more common in females. Dr. Tara Gomes, lead investigator and program director of the Ontario Drug Policy Research Network, highlights that while the data may reflect enhanced recognition and treatment of adult ADHD, the rapid escalation in prescribing rates invites scrutiny regarding diagnostic accuracy and appropriateness of prescribing practices.
Encouragingly, heightened awareness of adult ADHD, partly supported by expanded healthcare access during the pandemic, especially through virtual care platforms, appears to have improved care pathways. Nonetheless, Dr. Mina Tadrous, coauthor and associate professor at the University of Toronto’s Leslie Dan Faculty of Pharmacy, cautions that the explosive growth of social media content focused on ADHD may contribute to misdiagnoses. The proliferation of ADHD labels in online discourse, coupled with faster but potentially less thorough virtual assessments, increases the risk of inappropriate stimulant utilization, which can pose significant health hazards.
International comparisons underscore the global nature of these trends. Similar surges in adult stimulant prescriptions have been documented in countries such as the United States, Australia, the United Kingdom, and Finland. Proposed mechanisms include rising ADHD recognition among adults, escalated virtual healthcare access, augmented screen time leading to heightened symptom awareness or exaggeration, and increased psychological distress linked to the pandemic and its aftermath.
Complicating the clinical landscape is the documented overlap of stimulant prescriptions with mental health conditions beyond ADHD. Approximately a quarter of new stimulant recipients were diagnosed with anxiety, depression, or both. This broader prescribing context raises questions about whether stimulants are being utilized off-label to manage symptoms of mood and anxiety disorders, which traditionally require different treatment modalities, thereby potentially exposing patients to inappropriate pharmacotherapy and adverse effects.
The study also revealed significant shifts in the professional profiles of prescribers. Prescriptions originating from psychiatrists dropped from 26% pre-pandemic to 18% post-pandemic, whereas initiation by nurses and nurse practitioners quintupled, moving from 2% to 10%. This evolution likely reflects healthcare system adaptations including workforce strain, expanded scopes of practice, and broader reliance on non-specialist providers. While such adaptations increase access, they underscore urgent needs for rigorous training and standardized protocols to safeguard diagnostic integrity and ensure respectful pharmacological stewardship.
Clinical diagnosis of adult ADHD demands meticulous assessment, integrating developmental history, symptom severity, functional impairment, and exclusion of differential diagnoses. The observed acceleration of stimulant prescribing amidst evolving healthcare delivery models, characterized by brief virtual consultations and non-specialist involvement, raises concerns about the adequacy of evaluations and the potential for both overdiagnosis and underdiagnosis. Misapplication of stimulant therapy can risk adverse cardiovascular, psychiatric, and dependency-related outcomes, necessitating vigilance.
This research acts as a clarion call for ongoing surveillance and multi-disciplinary dialogue aimed at balancing the benefits of increased adult ADHD recognition and timely treatment against emerging hazards related to rapid prescribing growth and diagnostic ambiguity. Stakeholders including clinicians, policymakers, educators, and patients must collaboratively prioritize enhanced diagnostic rigor, evidence-based prescribing, and patient safety in this evolving therapeutic frontier.
Ultimately, comprehensive strategies integrating public education, clinician training, equitable healthcare access, and robust pharmacovigilance are essential to optimize clinical outcomes. By recognizing the complexity of adult ADHD management in the post-pandemic era, health systems can align innovation in care delivery with established clinical standards, thereby minimizing harm while addressing an often-overlooked segment of mental health.
Subject of Research: People
Article Title: Patterns of prescription stimulant initiation before and during the COVID-19 pandemic: a population-based time series analysis
News Publication Date: 9-Mar-2026
Web References: http://dx.doi.org/10.1503/cmaj.251065
Keywords: Attention deficit hyperactivity disorder, Adult ADHD, Stimulant prescriptions, COVID-19 pandemic, Virtual healthcare, ADHD diagnosis, Mental health prescribing trends, Psychostimulant utilization, Gender differences in ADHD, Misdiagnosis, Healthcare policy, Pharmacological treatment
